Andon Health Co., Ltd (SHE: 002432), a healthcare company based in China, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for two of its COVID-19 testing products. The first is the iHealth COVID-19/Flu A&B Rapid Test Pro, a triple detection point-of-care (POC) kit designed to qualitatively detect and differentiate between influenza A and B viruses and the novel coronavirus from anterior nasal swab samples within four days of the onset of respiratory symptoms. The second product is the iHealth COVID-19 Antigen Rapid Test, an over-the-counter (OTC) kit intended for the rapid and qualitative detection of the novel coronavirus (SARS-CoV-2) in human anterior nasal swab samples.
The iHealth COVID-19/Flu A&B Rapid Test Pro is approved for prescription use in nursing facilities, providing a diagnostic tool to distinguish between common respiratory infections. The iHealth COVID-19 Antigen Rapid Test offers a convenient option for at-home testing, contributing to the accessibility of COVID-19 detection.- Flcube.com
